tiprankstipranks
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
US Market

Acrivon Therapeutics, Inc. (ACRV) Stock News & Sentiment

119 Followers
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
PremiumPress Releases
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
2M ago
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
PremiumPress Releases
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
2M ago
Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
PremiumCompany Announcements
Acrivon Therapeutics Reports Breakthrough Results and Solid Finances
3M ago
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
PremiumPress Releases
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
3M ago
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
PremiumPress Releases
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
3M ago
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
PremiumPress Releases
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
3M ago
Acrivon Therapeutics Secures $130M for Drug Development Expansion
PremiumCompany Announcements
Acrivon Therapeutics Secures $130M for Drug Development Expansion
3M ago
More ACRV News >

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ACRV’s Media Buzz Sentiment?
Currently, no data Available
What is ACRV’s weekly average amount of articles?
Currently, no data Available
What is ACRV’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
GMEDGlobus Medical
ISRGIntuitive Surgical
UNHUnitedHealth
EWTXEdgewise Therapeutics
PENPenumbra
Showing the stocks with the most bullish news sentiment over the past week
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis